Abstract OT2-01-01: Phase 1 Study of ST101, a First-in-class Peptide Antagonist of CCAAT/enhancer-binding Protein Β (c/ebpβ), in Patients with Advanced Solid Tumors, with a Phase 2 Expansion in Patients with Hormone Receptor Positive Breast Cancer (HR+ BC)
Cancer Research（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined